Diabetes

February 19, 2021

Published by admin_auro at February 19, 2021

Categories

Mechanistic insights into how Semaglutide functions as an anti-obesity/diabetic drug : Semaglutide-based therapy for TIIDM and obesity-associated metabolic deficits: Semaglutide (trade name:Victoza, Saxenda), a glucagon-like peptide-1 agonist used in the treatment of diabetes, increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, decreases TXNIP expression, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM, via down-regulation of its target gene, 19/February/2021, 10.43 pm

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent […]

March 9, 2020

Published by admin_auro at March 9, 2020

Categories

Curing, preventing and reversing diabetes with a commonly available antiasthmatic drug Montelukast: Montelukast-based therapy for TIIDM and obesity-associated metabolic deficits: Montelukast (trade name: Singulair and others), a vasodilator used in the treatment of asthma, increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, decreases TXNIP expression, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM, via down-regulation of its target gene, 9/March/2020, 11.08 pm

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent […]

February 24, 2020

Published by admin_auro at February 24, 2020

Categories

Molecular therapy for body weight control, energy homeostasis and TIIDM: TICAM1/TRIF[Toll-like receptor adaptor molecule1/TIR-domain-containing adapter-inducing interferon-beta] decreases CADM1 and its downstream target genes that inhibit glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 24/February/2020, 11.12 pm

Introduction: What they say A study from the Max Delbrück Center for Molecular Medicine, Berlin, Germany shows that “Regulation of body weight and energy homeostasis by […]

November 14, 2019

Published by admin_auro at November 14, 2019

Categories

Curing, preventing and reversing diabetes with a commonly available blood pressure drug Hydralazine: Hydralazine-based therapy for TIIDM and obesity-associated metabolic deficits: Hydralazine (trade name: Apresoline, BiDil, and others), a vasodilator used in the treatment of high blood pressure, cardiac failure and others, increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, decreases TXNIP expression, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM, via down-regulation of its target gene, 14/November/2019, 9.58 am

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent […]